

Reference:	FOI.6914.21
Subject:	Prostate cancer
Date of Request:	16 September 2021

Request and response:

In any multiple-choice questions, we ask that you please indicate your answer by marking with an “X” next to any answers that apply or by deleting all answers that do not apply. Please avoid answering by italics, underlining or bold, as these do not show up when we process your response.

1. Does your trust/HB have access to PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients?

Hywel Dda University Health Board (UHB) has deleted all answers that do not apply below.

- b. Not on site, but we refer patients elsewhere (please state the trust/HB patients are referred to, if possible:)

All patients requiring referral for PET-CT for the investigation of suspected biochemical recurrence in prostate cancer are referred onto Swansea Bay University Health Board.

2. If you answered “No” to question 1. Would you use PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients if it were available?

The UHB has deleted all answers as they do not apply.

3. In 2020-21, how many patients do you estimate were investigated for suspected biochemical recurrence of prostate cancer at your trust/HB?

The UHB estimates that less than ten (10) patients were investigated for suspected biochemical recurrence of prostate cancer, during the 2020/21 financial year.

4. What percentage of patients with suspected biochemical recurrence do you estimate are referred for PET-CT at your trust/HB?

The UHB estimates that 20% or less of patients with suspected biochemical recurrence are referred for PET-CT. Cases are discussed within multi-disciplinary team (MDT) meetings and requests for referrals are only made for PET-CT if the results will influence treatment.

5. Of patients with suspected biochemical recurrence referred for PET-CT, what % of scans do you estimate use a PSMA tracer (either Ga-PSMA or F-PSMA)?

The UHB confirms that of patients with suspected biochemical recurrence referred for PET-CT that are qualified and authorised for PSMA PET, 100% will have a PSMA PET.

6. Are there any exclusion criteria for referral for PET-CT for suspected biochemical recurrence of prostate cancer? If so, what are they? E.g. Upper and lower PSA limits, age, life expectancy, ECOG score.

The UHB confirms that the exclusion criteria for referral for PET-CT for suspected biochemical recurrence of prostate cancer used to be a PSA limit of 0.5. However, this exclusion has now been relaxed. All suitable cases are discussed in MDT meetings where all factors (age, performance status and life expectancy) are taken into consideration.

7. What do you estimate is the average waiting time for the PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?

The UHB confirms that the average waiting time for the PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer is two (2) weeks.

8. What do you estimate is the average time it takes to report PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?

The UHB confirms that the average time it takes to report PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer varies. However, this is usually within a week.